Effectiveness of netarsudil 0.02% in lowering intraocular pressure in patients with secondary glaucoma

Oydanich, Marko; Roll, Elizabeth H.; Uppuluri, Siri; Khouri, Albert S

doi:10.1016/j.jcjo.2023.05.009

Cited by 2 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Netarsudil has The effectiveness of netarsudil in specific clinical sub-cohorts, such as secondary glaucoma and patients on maximal tolerated medical therapy, is still being explored. Preliminary evidence suggests that netarsudil can provide additional IOP-lowering effects in patients with uveitic glaucoma on maximal tolerated medical therapy [59]. Netarsudil has also been shown to be effective in a cohort of patients with Sturge-Weber Syndrome on maximal medical therapy by reducing EVP [60], and it demonstrated similar efficacy to latanoprostene bunod when used as adjunct therapy in patients on maximal therapy for POAG [61].…”

Section: Netarsudil In Glaucomamentioning

confidence: 98%

“…The effectiveness of netarsudil in specific clinical sub-cohorts, such as secondary glaucoma and patients on maximal tolerated medical therapy, is still being explored. Preliminary evidence suggests that netarsudil can provide additional IOP-lowering effects in patients with uveitic glaucoma on maximal tolerated medical therapy [59]. Netarsudil has The effectiveness of netarsudil in specific clinical sub-cohorts, such as secondary glaucoma and patients on maximal tolerated medical therapy, is still being explored.…”

Section: Netarsudil In Glaucomamentioning

confidence: 99%

See 1 more Smart Citation

ROCK Inhibitors in Corneal Diseases and Glaucoma—A Comprehensive Review of These Emerging Drugs

Pagano,

Lee,

Posarelli

et al. 2023

JCM

View full text Add to dashboard Cite

Rho kinase (ROCK) inhibitors have gained significant attention as emerging novel treatment options in the field of ophthalmology in recent years. The evidence supporting their efficacy in glaucoma and corneal pathology includes both in vitro and clinical studies. Among the available options, ripasudil and netarsudil have emerged as the leading ROCK inhibitors, and some countries have approved these therapeutic options as treatments for glaucoma. Various dosing regimens have been studied, including monotherapy and combination therapy, especially for patients with secondary glaucoma who are already on multiple medications. Another rising application of ROCK inhibitors includes their use as an adjunct in surgical procedures such as Descemetorhexis Without Endothelial Keratoplasty (DWEK), Descemet Stripping Only (DSO) to accelerate visual recovery, glaucoma surgeries to reduce scarring process and allow better intraocular pressure (IOP) control, or after complicated anterior segment surgery to treat corneal oedema. This article provides a comprehensive overview of the existing literature in the field, offering recommendations for prescribing ROCK inhibitors and also discussing patient selection, drug efficacy, and possible adverse effects.

show abstract

Section: Netarsudil In Glaucomamentioning

confidence: 98%

Section: Netarsudil In Glaucomamentioning

confidence: 99%